Events After the End of the Reporting Period

Repayment of financial liabilities

The syndicated credit facility drawn in June 2018 to finance the acquisition of Monsanto was reduced by a further US$1.1 billion to US$3.8 billion in February 2019.

PEGylated factor VIII:

In February 2019, a federal court jury awarded US$155 million in damages to Bayer at the end of a trial regarding Bayer’s claims against Baxalta Incorporated and Baxalta US Inc. (Baxalta) for infringement of a Bayer patent. In 2016, Bayer had filed a complaint in a U.S. federal court against Baxalta, a subsidiary of Takeda Pharmaceutical Company Limited, for infringement of the patent by Adynovate™ (PEGylated recombinant factor VIII), approved in the United States for the treatment of hemophilia. Baxalta may appeal.

Leverkusen, February 19, 2019

Bayer Aktiengesellschaft

The Board of Management

Compare to Last Year